166 related articles for article (PubMed ID: 33955334)
1.
Chowrasia D; Jafri A; Azad I; Rais J; Sharma N; Khan F; Kumar A; Kumar S; Arshad M
J Biomol Struct Dyn; 2022 Nov; 40(18):8569-8586. PubMed ID: 33955334
[TBL] [Abstract][Full Text] [Related]
2. Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.
Khan T; Ahmad R; Azad I; Raza S; Joshi S; Khan AR
Comput Biol Chem; 2018 Aug; 75():178-195. PubMed ID: 29883916
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, ADMET predictions, molecular docking studies, and
Sulistyowaty MI; Widyowati R; Putra GS; Budiati T; Matsunami K
J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):385-392. PubMed ID: 34214332
[TBL] [Abstract][Full Text] [Related]
4. Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents.
Azad I; Nasibullah M; Khan T; Hassan F; Akhter Y
J Mol Graph Model; 2018 May; 81():211-228. PubMed ID: 29609141
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, biological evaluation and molecular docking of a new quinazolinone-based derivative as a potent dual inhibitor for VEGFR-2 and EGFR tyrosine kinases.
Riadi Y; Alamri MA; Geesi MH; Anouar EH; Ouerghi O; Alabbas AB; Alossaimi MA; Altharawi A; Dehbi O; Alqahtani SM
J Biomol Struct Dyn; 2022 Sep; 40(15):6810-6816. PubMed ID: 33682611
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric 1,5-diarylpenta-1,4-dien-3-ones: Antiproliferative activity in prostate epithelial cell models and pharmacokinetic studies.
Zhang X; Guo S; Chen C; Perez GR; Zhang C; Patanapongpibul M; Subrahmanyam N; Wang R; Keith J; Chen G; Dong Y; Zhang Q; Zhong Q; Zheng S; Wang G; Chen QH
Eur J Med Chem; 2017 Sep; 137():263-279. PubMed ID: 28601720
[TBL] [Abstract][Full Text] [Related]
9. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
10. In-silico and in-vitro anti-cancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione.
Sufi SA; Adigopula LN; Syed SB; Mukherjee V; Coumar MS; Rao HS; Rajagopalan R
Biomed Pharmacother; 2017 Jan; 85():389-398. PubMed ID: 27889234
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
12. A New Series of Triazolothiadiazines as Potential Anticancer Agents for Targeted Therapy of Non-Small Cell Lung and Colorectal Cancers: Design, Synthesis, In silico and In vitro Studies Providing Mechanistic Insight into Their Anticancer Potencies.
Sever B; Altıntop MD; Çiftçi GA; Özdemir A
Med Chem; 2021; 17(10):1104-1128. PubMed ID: 33087032
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of curcumin inspired imidazo[1,2-a]pyridine analogues as tubulin polymerization inhibitors.
Ramya PVS; Guntuku L; Angapelly S; Digwal CS; Lakshmi UJ; Sigalapalli DK; Babu BN; Naidu VGM; Kamal A
Eur J Med Chem; 2018 Jan; 143():216-231. PubMed ID: 29174816
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Substituted 2-oxoquinolinylthiazolidin-4-one Analogues as Potential EGFRK Inhibitors in Lung Cancer Treatment.
Naik S; Soumya V; Mamledesai SN; Manickavasagam M; Choudhari P; Rathod S
Drug Res (Stuttg); 2024 Jun; 74(5):227-240. PubMed ID: 38830371
[TBL] [Abstract][Full Text] [Related]
15. Chloro and bromo-pyrazole curcumin Knoevenagel condensates augmented anticancer activity against human cervical cancer cells: design, synthesis,
Chaudhary M; Kumar N; Baldi A; Chandra R; Arockia Babu M; Madan J
J Biomol Struct Dyn; 2020 Jan; 38(1):200-218. PubMed ID: 30784365
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells.
Ragab FAF; Abdel-Aziz SA; Kamel M; Ouf AMA; Allam HA
Bioorg Chem; 2019 Dec; 93():103323. PubMed ID: 31586713
[TBL] [Abstract][Full Text] [Related]
17. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
18. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
20. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
